PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
32.68%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
80.19%
D&A growth of 80.19% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
-398.37%
Negative yoy deferred tax while RVPH stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
30.65%
SBC growth while RVPH is negative at -56.99%. John Neff would see competitor possibly controlling share issuance more tightly.
27.89%
Less working capital growth vs. RVPH's 125.07%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.29%
Negative yoy AP while RVPH is 101.70%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
66.06%
Lower 'other working capital' growth vs. RVPH's 159.63%. David Dodd would see fewer unexpected short-term demands on cash.
30.65%
Lower 'other non-cash' growth vs. RVPH's 81.82%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-19.98%
Negative yoy CFO while RVPH is 38.83%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-32.37%
Negative yoy CapEx while RVPH is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-271.58%
We reduce yoy invests while RVPH stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
69.11%
Debt repayment 1.25-1.5x RVPH's 52.51%. Bruce Berkowitz would see an edge in lowering interest burdens unless competitor invests in profitable expansions.
-69.14%
Negative yoy issuance while RVPH is 4129.39%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.